AG00I5DR

288383-20-0 | 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline

AG00I5DR

SDS

COA

Price

$0.00

Add to Cart

Buy Now

WARNING This product is not for human or veterinary use.

CAS Number	288383-20-0
Catalog Number	AG00I5DR(AGN-PC-0R4MCG)
Chemical Name	4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
IUPAC Name	4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline
InChI	InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3
InChI Key	XXJWYDDUDKYVKI-UHFFFAOYSA-N
MDL Number	MFCD09954115
Molecular Formula	C25H27FN4O3
Molecular Weight	450.5053
SMILES	FC1=C2C=C(NC2=CC=C1OC1=NC=NC2=CC(=C(C=C12)OC)OCCCN1CCCC1)C
UNII	NQU9IPY4K9
Synonyms	4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline, AZD 2171, AZD-2171, AZD2171, cediranib, Cediranib, 288383-20-0, Recentin, AZD2171, Cediranib (AZD2171), Cedirannib, AZD 2171, AZD-2171, Cediranib (AZD217), UNII-NQU9IPY4K9, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline, 4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline, NQU9IPY4K9, ZD-2171, CHEMBL491473, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline, NSC-732208, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline, Q-101399, C25H27FN4O3, Cediranib (USAN/INN), Cediranib [USAN:INN:BAN], 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline, Cediranib,AZD2171, Kinome_3318, Cediranib dihydrochloride, AZD2171, Cediranib, M6294, Cediranib - AZD2171, SCHEMBL63147, MLS006010063, GTPL5664, QCR-93, Cediranib (AZD2171)/Recentin, CHEBI:94782, AOB1949, DTXSID10183035, XXJWYDDUDKYVKI-UHFFFAOYSA-N, BCPP000295, HMS3654G05, BCP01378, EX-A2039, KS-00000LF1, ZINC3948085, ABP000861, AN-567, BDBM50331096, MFCD09954115, s1017, AKOS005145767, BCP9000500, CS-0119, DB04849, ES-0052, RL02984, SB16536, ZD 2171, NCGC00263097-01, NCGC00263097-09, AC-25033, AK340948, AT-19598, BC667561, HY-10205, SC-23199, SMR004701223, AB0030443, FT-0751000, SW219261-1, X2636, EC-000.2328, A10185, A24280, D08881, W-5429, P111005, BRD-K86930074-001-01-9, 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline, 4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-yl-propoxy)-quinazoline, Quinazoline, 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(1-pyrrolidinyl)propoxy)-, Quinazoline,4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-, Cadiranib, Cediranib [INN], D09VMI, cc-438, AZD2171, Recentin, Cediranib, ACN-034651, CID9933475, A1882, C500926,

Complexity	625
Compound Is Canonicalized	Yes
Covalently-Bonded Unit Count	1
Defined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Exact Mass	450.207g/mol
Formal Charge	0
Heavy Atom Count	33
Hydrogen Bond Acceptor Count	7
Hydrogen Bond Donor Count	1
Isotope Atom Count	0
Molecular Weight	450.514g/mol
Monoisotopic Mass	450.207g/mol
Rotatable Bond Count	8
Topological Polar Surface Area	72.5A^2
Undefined Atom Stereocenter Count	0
Undefined Bond Stereocenter Count	0
XLogP3	4.9

GHS Hazard and Precautionary Statements

Symbol:
Hazard Class
Hazard statements	H302-H315-H319-H335
Packing Group
Precautionary statements	P261-P305+P351+P338
UN Code

Certificate of Analysis

Lot Number